Home Trending Stocks Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the pre-market trading session. Atossa Therapeutics is a clinical-stage biopharmaceutical business focused on discovering and developing new medications in unmet medical needs, with a current emphasis on breast cancer and COVID-19.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Significant Development

ATOS has released the final results of its Phase 2 clinical research of oral Endoxifen given within the “window of opportunity” between breast cancer diagnosis and surgery.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

  • Primary Endpoint Met: Ki-67 was found to be reduced. Ki-67, a frequent indicator of tumor cell activity, was decreased by 65.1 percent from 25.6% at the screening to 6% on the day of surgery. Ki-67 was lowered by less than 25% in all patients, which might be clinically significant because past studies have demonstrated that a decrease of less than 25% improves long-term survival.

The following were the secondary endpoints:

Tolerance and safety: All adverse events were minimal and thought to be attributable to the study medication. There were no variations in vital signs, physical exams, or ECGs, and no aberrant laboratory findings (serum chemistry, hematology, coagulation, and urinalysis). Endoxifen was found to be safe and well-tolerated in this investigation based on these findings. The trial was not terminated due to any adverse occurrences.

Read More

Other findings: Estrogen receptor expression declined from 100% attesting to 88.6% on operation day, but progesterone receptor expression rose from 84.3 percent to 92.9 percent. There was no link discovered between Ki-67 expression and Endoxifen levels.

Steven Quay, Atossa’s President, and Chief Executive Officer stated:

Based on these encouraging results, they are taking a variety of efforts to accelerate Endoxifen development.  ATOS has started the official non-clinical toxicology study that will be required for a New Drug Application to gain marketing clearance for Endoxifen, and they want to submit to the US FDA as soon as feasible for authorization to perform clinical research here in the US. The next clinical trial will quantify pathological full response in the neoadjuvant context, according to their expectations. Despite the fact that there are many FDA-approved neoadjuvant treatments for breast cancers that are not estrogen receptor positive (ER+), there are presently very few approved therapies for the nearly 78 percent of breast cancers that are ER+, which they believe creates a significant unmet need for their Endoxifen.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Why is Autolus Therapeutics plc (AUTL) stock rising today?

Shares of  Autolus Therapeutics plc (AUTL) stock were rising today on June 11, 2021, following the release of the presentation data related to obe-cel...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Related News

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Root, Inc. (ROOT) Stock Surges After Becoming Latest Target of Meme Stock Phenomenon Gripping the Market

Root, Inc. (ROOT) stock prices were up by a significant 20.87% shortly after market trading commenced on June 9th, 2021, bringing the price per...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam